BioPharma Resources

Company

UCB

Includes drugs filed under related and acquired sponsor names. Trials are searched under: UCB Biopharma SRL; UCB Pharma.

Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov

NDAs and BLAs

30

18 still marketed

Novel approvals

11

Approvals since 2021

22

Originals and new uses

Phase 3 trials

189

Registered, any status

Trials by phase

All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.

Recent approvals

Originals and efficacy supplements, newest first.

Drugs in development (5)

Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.

Open in pipeline
  • DZPCDP7657, Dapirolizumab pegolPhase 32 trials

    UCB · Systemic Lupus Erythematosus

  • Staccato alprazolamUCB7538Phase 32 trials

    UCB · Stereotypical Prolonged Seizures

  • GalvokimigUCB9741Phase 23 trials

    UCB · Chronic Obstructive Pulmonary Disease With Chronic Bronchitis, Atopic Dermatitis, Non-cystic Fibrosis Bronchiectasis

  • UCB0022Phase 21 trial

    UCB · Parkinson Disease

  • UCB1381Phase 21 trial

    UCB · Atopic Dermatitis

Recruiting Phase 3 trials

Largest first.

Marketed drugs (18)

Newest FDA action first.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.